| Date | Title | Description |
| 24.04.2025 | SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy | Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise
Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercializat... |
| 24.04.2025 | Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform | Aarhus, Denmark, 28 January 2025, Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces a €5.5m extension to its seed financing. The contribution from new i... |
| 24.04.2025 | SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) | DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) — SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today ... |
| 24.04.2025 | Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030 | Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects ... |
| 22.01.2025 | Bioqube Ventures Unveils Spica Therapeutics to Pioneer Macrophage-Subset Targeted Therapies | Brussels, Belgium, January 9, 2025 – Spica Therapeutics (“Spica”), a pioneering biotech company focused on macrophage biology, today announced its emergence from stealth mode, supported by Bioqube Ventures. Headquartered in Belgium, with a ... |
| 15.01.2025 | Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors | Aarhus, Denmark, 8 January 2025 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors... |
| 15.01.2025 | Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer | Paris, France, January 13, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of... |
| 15.01.2025 | CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab | Munich, Germany and San Francisco, USA, January 09, 2025 – CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, ... |
| 22.12.2024 | SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial | Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors
Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment... |
| 22.12.2024 | Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer | Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Mikkel Wandahl Pedersen as Chief Scientific Offi... |
| 17.10.2024 | Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US | Leiden, The Netherlands – October 9, 2024 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, today announced the appointment of Edward Holson, Ph.D., as Chief Scientific Officer (CSO). ... |
| 21.09.2024 | Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the cl... |
| 07.09.2024 | Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease | Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdi... |
| 07.09.2024 | Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever | – PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses –
SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate... |
| 07.09.2024 | Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | First-in-class bifunctional EGFR/TGF-β inhibitor, ficerafusp alfa, in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity and significant improvement over standard of care in HNSCC with at least 12 mont... |
| 07.09.2024 | Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development | BOSTON, Mass., March 26, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as ... |
| 07.09.2024 | SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT | Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led... |
| 07.09.2024 | Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer | Cambridge, UK, 15 May 2024: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as ... |
| 07.09.2024 | CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab | Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunit... |
| 07.09.2024 | Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting | April 04, 2024 03:30 PM Eastern Daylight Time
Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting
In the poster, entitled “EGL-001 is a novel immunocytokine... |
| 07.09.2024 | EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Indepen... | Paris, France, May [date], 2024 – EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appoin... |
| 07.09.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital | • SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody
• Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 07.09.2024 | Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. | BOSTON, Mass., August 15, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the appointments of Mike Powell, Ph.D., and Christ... |
| 08.02.2024 | Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer | Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships
Cambridge, UK, 31 January 2024 – Enhanc3D Genomics, a company developing di... |
| 10.01.2024 | Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing | Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) |
| 01.11.2023 | Bicara Therapeutics Expands Board of Directors with Appointments of Kate Haviland and Scott Robertson | Boston, Mass., October 16, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the expansion of its board of directors with the ... |
| 01.11.2023 | Anavo Therapeutics strengthens management team | The company appoints industry veteran Shaun McNulty as Chief Scientific Officer and welcomes R&D expert Anna Quattropani as Senior Vice President of Chemistry & Non-Clinical Development |
| 01.11.2023 | Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting | |
| 01.11.2023 | Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023 | First-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, in combination with pembrolizumab continues to demonstrate clinically meaningful preliminary anti-tumor activity consistent with previous results |
| 04.08.2023 | Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer | CAMBRIDGE, Mass., July 24, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David Raben, M.D., as chief me... |
| 07.07.2023 | Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cel... | Phase 1/1b results to be highlighted in an oral presentation at 2023 ASCO Annual Meeting |
| 07.07.2023 | Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting | SAN DIEGO, March 14, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancero... |
| 05.05.2023 | Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic | Leiden, The Netherlands, and Heidelberg, Germany, May 2, 2023 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, announced today an EUR 8.5 million seed round extension, adding MR... |
| 22.04.2023 | Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101 | April 19, 2023 |
| 22.04.2023 | Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting | — PRTX007 was shown to be well-tolerated with a favorable safety profile for all analyzed cohorts in the Phase 1 study — |
| 24.03.2023 | Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer | Financing will support future studies of lead program BCA101, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth |
| 21.10.2022 | Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform | Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A ... |
| 12.10.2022 | TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP FIRST-IN-CLASS IMMUNE CHECKPOINT AGONISTS | Paris, France, September 15, 2022 – Tridek-One SAS (the ‘Company’), a leading biotech start- up specialized in the research and development of CD31 agonists to restore the immune balance, today announces it has closed a €16 million ($16.1M)... |
| 23.06.2022 | ENHANC3D GENOMICS Awarded QuickFire Challenge Grant | Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Joh... |
| - | Bioqube Ventures launches Bioqube Factory Fund I | June 10th – Hasselt/Brussels, Belgium – Bioqube Ventures announces today the first closing of Bioqube Factory Fund I, a new early stage venture capital fund focused on the development of therapeutic assets and technology platforms in Europe... |
| - | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers | LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate |
| - | Lonza and Bioqube Ventures Sign a Framework Agreement for the Future Development and Manufacture of Biologics and Small Molecules for Bioqube’s Portfolio Companies | Basel, Switzerland, 30 November 2021 – Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition... |
| - | Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™ | SAN DIEGO, November 2, 2021 – Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acut... |
| - | Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators | Seed round was led by M Ventures and INKEF Capital, and co-led by Taiho Ventures and Bioqube Ventures |
| - | Primmune Therapeutics Strengthens Leadership Team with Key Appointments | SAN DIEGO, February 5, 2021 – Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Develop... |
| - | Primmune Therapeutics Announces Close of Series A Financing | SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of ... |
| - | Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology | Karl-Heinz Altmann, Andrew Mortlock and Gregg Siegal to join Anavo’s SAB |
| - | Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster | Leiden, The Netherlands, and Heidelberg, Germany, August 16, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced that the company has partnered with BioLabs Gl... |
| - | Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing | SAN DIEGO, November 4, 2021 – Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These... |
| - | Bioqube Ventures welcomes two seasoned professionals | Brussels/Hasselt, Belgium – 24th September 2020 – Bioqube Ventures, a European life sciences venture capital firm, today announces that Tom Heyman joins Bioqube Ventures as Operating Partner and Peter Verhaeghe will chair the LP and Advisor... |
